title: Predictors of arrhythmia recurrence in patients with lone atrial fibrillation.
abstract: OBJECTIVE
  The need for antiarrhythmic drugs (AAD) after a first episode of atrial fibrillation (AF) is determined by the probability of recurrence. The aim of this study was to asses the probability of relapse and the predictors of recurrence in patients with idiopathic AF.
  
  
  RESULTS
  A cohort of 98 consecutive patients younger than 65 years admitted at the emergency room because of an episode of symptomatic idiopathic (lone) AF was included in this study. On admission, a complete medical history was taken, and an echocardiogram and 24-h Holter monitoring were performed. Patients were seen at 3 and 6 months after the index episode. There were 35 (35.7%) patients with a new-onset AF episode and 63 (64.3%) with a recurrent AF episode. A majority of them were male (71%), with a mean age of 48+/-11 years. Patients with new-onset AF episodes did not receive AAD. At 6 month follow-up, 57% of all patients suffered at least one symptomatic AF relapse. Patients with AF relapses belong more often to the recurrent group vs. new-onset group of AF (65.1 vs. 34.9%, respectively, P = 0.03); they had larger LA diameter indexed for body surface area (BSA) (22.6+/-3.7 vs. 19.8+/-3.2 mm/m(2), P = 0.001), larger left ventricular end-systolic diameter (18.4+/-3.1 vs. 17.2+/-2.5 mm/m(2), P = 0.05) and a tendency towards a higher proportion of atrial tachycardia runs on Holter (66.7 vs. 50%, P = 0.09). Logistic regression analysis showed that the presence of previous episodes of AF (OR: 3.2; 95% CI; 1.0-8.0, P = 0.04) and a larger anteroposterior LA diameter (OR: 1.3; 95% CI; 1.1-1.6, P = 0.001) were independent predictors of AF recurrences at 6 months.
  
  
  CONCLUSIONS
  The recurrence rate in lone AF patients is high. The presence of previous episodes and a mildly enlarged anteroposterior LA diameter increase the probability of relapse of lone AF.
authors.affiliation: Thorax Institute, Hospital Clínic, University of Barcelona, Villarroel 170, Barcelona 08036, Catalonia, Spain.
authors.forename: Germán
authors.initials: G
authors.lastname: Arriagada
authors.forename: Antonio
authors.initials: A
authors.lastname: Berruezo
authors.forename: Lluís
authors.initials: L
authors.lastname: Mont
authors.forename: David
authors.initials: D
authors.lastname: Tamborero
authors.forename: Irma
authors.initials: I
authors.lastname: Molina
authors.forename: Blanca
authors.initials: B
authors.lastname: Coll-Vinent
authors.forename: Bárbara
authors.initials: B
authors.lastname: Vidal
authors.forename: Marta
authors.initials: M
authors.lastname: Sitges
authors.forename: Paola
authors.initials: P
authors.lastname: Berne
authors.forename: Josep
authors.initials: J
authors.lastname: Brugada
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D015331:Cohort Studies; D004452:Echocardiography; D004562:Electrocardiography; D015716:Electrocardiography, Ambulatory; D005260:Female; D006325:Heart Atria / Q000000981:diagnostic imaging / Q000473:pathology*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012008:Recurrence
chemical_list: D000889:Anti-Arrhythmia Agents